So ketamine doesn't grow new brain cells?

Probably not in the classical neurogenesis sense, at least not reliably in humans. What ketamine has been shown to do, in animal models and supporting human imaging, is grow new synaptic connections between existing neurons. That is synaptogenesis, and it is arguably more functionally meaningful for depression than producing brand-new neurons would be.

Why does this distinction matter — isn't it the same idea?

It matters because the timescale and biology are different. Synaptogenesis happens within hours of a single dose in animal studies. Classical neurogenesis is slow, restricted to specific brain regions like the hippocampus, and the evidence that it occurs at meaningful levels in adult humans remains contested. Conflating the two oversells the science.

Will ketamine grow my brain back to where it was before depression?

The honest answer is that animal studies show ketamine restores stress-related synaptic loss in the prefrontal cortex. Whether human brains do exactly the same thing, in the same magnitude, is supported by indirect evidence rather than direct counts of synapses. We avoid hype framing because the real story is good enough on its own merits.

Will exercise or sleep do the same thing?

Both exercise and deep sleep support synaptic health and BDNF signaling through different mechanisms. They are complementary to ketamine, not substitutes, especially for treatment-resistant depression. We encourage patients to think of ketamine as part of a broader plan that includes movement, sleep, and behavioral change.

Does the new synaptic growth last?

Animal data suggests structural changes from a single dose persist for at least a week or two, sometimes longer. Sustained recovery in humans typically requires a series of infusions plus integration of behavioral change while the brain is in a more plastic state. Marla Peterson, CRNA, oversees every infusion at Music City Ketamine and helps patients plan for that broader arc.

Ketamine and Neurogenesis: What's Actually Happening in the Brain

Neurogenesis vs. synaptogenesis: the distinction that matters

If you have read anything online about how ketamine works for depression, you have probably seen the word “neurogenesis.” It sounds dramatic and hopeful. New brain cells. Growing your way out of depression. The trouble is that the science behind ketamine does not really support that framing. The actual mechanism is more specific, faster, and in some ways more interesting.

Neurogenesis, in the textbook sense, means the birth of new neurons. In adult mammals it has been documented mostly in two regions: the dentate gyrus of the hippocampus and the subventricular zone. Whether adult human neurogenesis happens at clinically meaningful rates is still debated in the literature. Some studies say yes, others say barely. It is slow biology. New neurons take weeks to mature and integrate.

Synaptogenesis is different. It is the formation of new synapses—the physical connection points between neurons. This is what ketamine has been shown to drive, particularly in the prefrontal cortex, and it happens within hours of a single dose. The neurons themselves are not new. The wiring between them is.

This distinction is not a pedantic footnote. It changes the timeline, the mechanism, and the honest answer to the question patients keep asking us in Franklin: “Is ketamine actually growing my brain back?”

Why chronic stress causes synaptic loss in the first place

To understand why synaptogenesis matters, you have to understand what depression appears to be doing to the brain at a structural level. The synaptic-plasticity model of depression, articulated most clearly by Duman, Aghajanian, Sanacora and Krystal in a 2016 review in Nature Medicine, frames depression as a problem of dendritic atrophy and synaptic loss in the prefrontal cortex and hippocampus.

Chronic stress drives elevated glutamate and glucocorticoid signaling. Over time, dendrites—the branch-like projections that receive signals from other neurons—retract. Dendritic spines, the tiny protrusions where individual synapses live, disappear. The neurons are still there. The connections between them are not.

This is consistent with what postmortem and imaging studies see in people who lived with severe depression: smaller hippocampi, reduced gray matter volume in the prefrontal cortex, and altered functional connectivity. Sanacora, Treccani and Popoli argued in Neuropharmacology in 2012 that depression is best understood as a problem of glutamate-driven dendritic remodeling, not of monoamine deficiency. It is a wiring problem.

If that framing is correct, then a treatment that can rapidly restore lost synaptic connections has a coherent mechanism for treating depression. That is the angle ketamine appears to come in from.

Li 2010: ketamine and dendritic spines in the prefrontal cortex

The foundational study here is Li and colleagues, published in Science in 2010. Working in rats, the researchers gave a single sub-anesthetic dose of ketamine and looked at the prefrontal cortex within hours. What they found reshaped how the field thought about rapid antidepressants.

The ketamine-treated animals showed increased dendritic spine density and elevated levels of synaptic proteins like PSD-95, GluR1, and synapsin I. The behavioral antidepressant-like effect tracked the structural changes. Block the mTOR pathway with rapamycin and you blocked both the synaptic effect and the behavioral effect. The structural change appeared to be doing the work.

This was striking for two reasons. First, the timescale: synapses were forming within hours, not weeks. Second, the location: the changes were in the prefrontal cortex, the region most clearly implicated in human depression. The rat data lined up with the regions where stress-related synaptic loss seems to matter most.

Autry and colleagues followed up in Nature in 2011, working in mice. They showed that ketamine triggered rapid BDNF protein synthesis in the hippocampus, and that BDNF and TrkB signaling were required for the antidepressant-like behavior. BDNF is the growth factor that supports new spine formation. The pieces fit together: NMDA receptor blockade, downstream BDNF release, mTOR activation, new synapses.

The mTOR pathway as the proximate driver

mTOR—mechanistic target of rapamycin—is the cellular switch that decides when to build new proteins, new spines, new synaptic machinery. It is normally suppressed in chronically stressed brains. Ketamine appears to flip it back on.

The proposed sequence, oversimplified: ketamine blocks NMDA receptors on a particular class of inhibitory interneurons. This briefly disinhibits glutamate release. The resulting glutamate surge activates AMPA receptors, which triggers BDNF release, which activates mTOR, which kicks off protein synthesis and dendritic spine formation. Hours later, the prefrontal cortex has more synaptic connections than it did before the infusion.

This mechanism is why people in ketamine clinics talk about a neuroplastic window after treatment. The brain is briefly in a state of heightened ability to rewire itself. That is also why the integration work patients do in the days and weeks after an infusion seems to matter so much—the wiring is more pliable than usual.

What the human imaging evidence actually shows

Here is where we have to be honest. Almost everything described above was demonstrated in rodents. We do not stain human brains for dendritic spines. We rely on indirect evidence.

What we do have in humans includes PET imaging studies showing increased synaptic density markers after ketamine in some patients, MRI evidence of normalized prefrontal connectivity, and clinical response patterns that fit the predicted timeline of a synaptic mechanism. None of that directly proves new spines are forming in human prefrontal cortex. It is consistent with the rodent story, but it is not the same as the rodent story.

The honest claim is this. The animal evidence for ketamine-driven synaptogenesis is robust and replicated. The human evidence is supportive but indirect. Research suggests the same biology is operating in people, but our tools for measuring it in living human brains are limited. Anyone who tells you ketamine has been proven to grow new synapses in human prefrontal cortex is overstating what the imaging actually shows.

Classical neurogenesis in adult humans, by contrast, has even thinner ketamine-specific evidence. Some animal work suggests ketamine modestly affects hippocampal neurogenesis under certain conditions, but the effect is inconsistent and is not the main story.

Why this isn't quite "growing new brain"

Ketamine is FDA-approved as an anesthetic. Its use for depression and other psychiatric conditions is off-label, with the exception of esketamine (Spravato), which is FDA-approved for treatment-resistant depression. We mention this every time we write about ketamine because it is the kind of thing patients deserve to know up front.

The marketing version of the ketamine story is “it grows new brain cells.” The accurate version is “it appears to rebuild synaptic connections that chronic stress eroded, primarily in the prefrontal cortex, and probably without producing many new neurons.” The accurate version is less catchy. It is also a better fit for what depression actually seems to be at a biological level.

You are not getting a different brain. You are getting a brain that, for a window of time, can rewire itself more easily than it normally can. What you do during that window—therapy, integration, sleep, exercise, behavioral change—matters as much as the infusion itself. The brain research we follow keeps reinforcing that point: the chemistry alone does not finish the work.

Honest framing for patients in Nashville

When patients ask us at Music City Ketamine whether ketamine causes neurogenesis, here is what we tell them. The science most likely supports synaptogenesis, not neurogenesis. The studies that get cited—Li 2010 in Science, Autry 2011 in Nature, the Duman 2016 review in Nature Medicine—are about new synaptic connections, not new neurons. We think that is good news, not a downgrade.

Synaptogenesis is faster, more localized to the regions that matter for depression, and more responsive to the kind of behavioral and therapeutic work patients do between infusions. The fact that the changes happen in hours is the reason ketamine can produce relief so much faster than traditional antidepressants. The way ketamine works is not magic. It is glutamate, BDNF, mTOR, and new spines, in roughly that order.

We also tell patients what the data does not support. We cannot promise that any individual will respond. Studies indicate that not everyone experiences the structural and clinical changes seen in the average. Evidence supports use in treatment-resistant depression, anxiety, PTSD, and some chronic pain conditions, but response varies. Our job is to be straight with people about that.

If you want to understand how the process works in our clinic, the short version is that Marla Peterson, CRNA, is in the room and oversees every infusion, with continuous monitoring throughout. Sessions are $475 each; we go into pricing in detail in our cost article. We do not stop or change your medications; that conversation belongs with your prescribing provider.

The honest version of the ketamine story is more interesting than the marketing version. We would rather tell you the honest version.